At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 65 enrolled
Drug / intervention
XEN45device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
In Brief
A Phase 3 clinical trial evaluating XEN45 for Glaucoma and Angle-Closure. Completed, enrolled 65 participants across 16 sites in 6 countries.
Detailed Summary
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Angle-Closure
CountriesAustralia, Canada, Singapore, South Korea, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJul 2018
Primary CompletionMar 2022
TodayJul 2026
First PostedDec 5, 2017
Enrollment StartJul 19, 2018
Primary CompletionMar 18, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.6 years ago
Interventions
XEN45device
XEN45 unilaterally implanted in the study eye